Table 1. Main clinical characteristics and parameters in 243 patients with pT1 ESCC.
| Variable | All patients, N=243 | LNM | P value | |
|---|---|---|---|---|
| Negative, N=197 | Positive, N=46 | |||
| Sex | 0.349a | |||
| Male | 160 (65.8%) | 127 (64.5%) | 33 (71.7%) | |
| Female | 83 (34.2%) | 70 (35.5%) | 13 (28.3%) | |
| Age (years) | 0.447a | |||
| <60 | 58 (23.9%) | 49 (24.9%) | 9 (19.6%) | |
| ≥60 | 185 (76.1%) | 148 (75.1%) | 37 (80.4%) | |
| Tumor location | 0.325a | |||
| Upper | 41 (16.9%) | 35 (17.8%) | 6 (13.0%) | |
| Middle | 161 (66.2%) | 132 (67.0%) | 29 (63.0%) | |
| Lower | 41 (16.9%) | 30 (15.2%) | 11 (23.9%) | |
| Degree of tumor differentiation | <0.001a,* | |||
| G1 | 92 (37.9%) | 80 (40.6%) | 12 (26.1%) | |
| G2 | 130 (53.5%) | 107 (54.3%) | 23 (50.0%) | |
| G3 | 21 (8.6%) | 10 (5.1%) | 11 (23.9%) | |
| T1 sub-stage | <0.001a,* | |||
| T1a | 88 (36.2%) | 83 (42.1%) | 5 (10.9%) | |
| T1b | 155 (63.8%) | 114 (57.9%) | 41 (89.1%) | |
| Tumor size (cm) | 0.002a,* | |||
| <2 | 90 (37.0%) | 82 (41.6%) | 8 (17.4%) | |
| ≥2 | 153 (63.0%) | 115 (58.4%) | 38 (82.6%) | |
| CEA (µg/L) | 2.39±1.53 | 2.45±1.54 | 2.14±1.50 | 0.222b |
| Neutrophil (109/L) | 4.46±1.99 | 4.52±2.09 | 4.23±1.48 | 0.381b |
| Lymphocyte (109/L) | 1.63±0.57 | 1.63±0.58 | 1.65±0.53 | 0.849b |
| LSR | 0.84±0.30 | 0.81±0.28 | 0.97±0.33 | 0.001b,* |
| HDL-C (mmol/L) | 1.30±0.31 | 1.26±0.29 | 1.44±0.35 | 0.001b,* |
*, P<0.05; a, Chi-square test; b, Student’s test; LNM, lymph node metastasis; ESCC, esophageal squamous cell carcinoma; CEA, carcinoembryonic antigen; LSR, alanine aminotransferase/aspartate aminotransferase ratio; HDL-C, high-density lipoprotein cholesterol.